Department of Physiology and Pharmacology, Western University, London, Canada.
Molecular Medicine Research Laboratories, Robarts Research Institute, London, Canada.
Stem Cells Dev. 2021 Mar;30(5):247-264. doi: 10.1089/scd.2020.0206. Epub 2021 Feb 19.
The secretome of mesenchymal stromal cells (MSCs) is enriched for biotherapeutic effectors contained within and independent of extracellular vesicles (EVs) that may support tissue regeneration as an injectable agent. We have demonstrated that the intrapancreatic injection of concentrated conditioned media (CM) produced by bone marrow MSC supports islet regeneration and restored glycemic control in hyperglycemic mice, ultimately providing a platform to elucidate components of the MSC secretome. Herein, we extend these findings using human pancreas-derived MSC (Panc-MSC) as "biofactories" to enrich for tissue regenerative stimuli housed within distinct compartments of the secretome. Specifically, we utilized 100 kDa ultrafiltration as a simple method to debulk protein mass and to enrich for EVs while concentrating the MSC secretome into an injectable volume for preclinical assessments in murine models of blood vessel and islet regeneration. EV enrichment (EV+) was validated using nanoscale flow cytometry and atomic force microscopy, in addition to the detection of classical EV markers CD9, CD81, and CD63 using label-free mass spectrometry. EV+ CM was predominately enriched with mediators of wound healing and epithelial-to-mesenchymal transition that supported functional regeneration in mesenchymal and nonmesenchymal tissues. For example, EV+ CM supported human microvascular endothelial cell tubule formation in vitro and enhanced the recovery of blood perfusion following intramuscular injection in nonobese diabetic/severe combined immunodeficiency mice with unilateral hind limb ischemia. Furthermore, EV+ CM increased islet number and β cell mass, elevated circulating insulin, and improved glycemic control following intrapancreatic injection in streptozotocin-treated mice. Collectively, this study provides foundational evidence that Panc-MSC, readily propagated from the subculture of human islets, may be utilized for regenerative medicine applications.
间充质基质细胞(MSC)的分泌组富含生物治疗效应物,这些效应物包含在细胞外囊泡(EV)内,也独立于 EV 存在,可作为注射剂支持组织再生。我们已经证明,骨髓 MSC 产生的浓缩条件培养基(CM)的胰腺内注射可支持胰岛再生,并恢复高血糖小鼠的血糖控制,最终为阐明 MSC 分泌组的成分提供了一个平台。在此,我们使用人胰腺来源的 MSC(Panc-MSC)作为“生物工厂”,扩展了这些发现,以富集分泌组中不同隔室中包含的组织再生刺激物。具体来说,我们利用 100 kDa 超滤作为一种简单的方法,在浓缩 MSC 分泌组为注射体积的同时,去除蛋白质质量并富集 EV,以进行血管和胰岛再生的小鼠模型的临床前评估。使用纳米流式细胞术和原子力显微镜验证了 EV 富集(EV+),此外,还使用无标记质谱法检测了经典 EV 标志物 CD9、CD81 和 CD63。EV+ CM 主要富含促进伤口愈合和上皮-间充质转化的介质,可支持间充质和非间充质组织的功能再生。例如,EV+ CM 支持人微血管内皮细胞体外小管形成,并增强非肥胖糖尿病/严重联合免疫缺陷小鼠单侧后肢缺血肌肉内注射后的血液灌注恢复。此外,EV+ CM 增加了胰岛数量和β细胞质量,提高了循环胰岛素水平,并改善了链脲佐菌素处理小鼠胰腺内注射后的血糖控制。总之,这项研究提供了基础证据,表明可从人胰岛的传代培养中轻易获得的 Panc-MSC 可用于再生医学应用。